Yes, I think we should at least be getting the development cost plus Phase II trial costs as upfront fees. About $18.5m.
However, the management seems to be quite confident about the outcome of Phase II as they mentioned many times that they want to go it alone with ATL1103. I am sure the licensing deal would be structured in a way that a much higher milestone payment upon successful Phase II.
From the TEVA experience with ATL1102, where they licensed it and subsequently buried it due to their own parallel development of a MS pill, I would want to see a termination payout clause for ATL1103 if the Pharma decided to terminate due to their own reason that is unrelated to the trial plan.
Deal or No deal? We have the fund for Phase II so there is no urgency to give away ATL1103 for anything less.
JIMO
- Forums
- ASX - By Stock
- PER
- various models on licensing negotiation
various models on licensing negotiation , page-7
-
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PER (ASX) to my watchlist
|
|||||
Last
8.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $72.12M |
Open | High | Low | Value | Volume |
8.3¢ | 8.4¢ | 8.0¢ | $99.06K | 1.226M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 3500 | 7.8¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
8.0¢ | 40625 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 3500 | 0.078 |
1 | 10000 | 0.077 |
1 | 180000 | 0.076 |
4 | 186800 | 0.075 |
3 | 180866 | 0.074 |
Price($) | Vol. | No. |
---|---|---|
0.080 | 40625 | 1 |
0.084 | 120000 | 1 |
0.085 | 363000 | 2 |
0.086 | 480000 | 3 |
0.087 | 400000 | 1 |
Last trade - 16.10pm 19/08/2024 (20 minute delay) ? |
Featured News
PER (ASX) Chart |